F. Stephen Hodi
Scientist
Ludwig Center at Harvard
Ludwig Institute for Cancer Research
United States of America
Biography
My primary research interest is in cancer immunotherapy, particularly the development of immune checkpoint inhibitors. My contributions to the field include the first human trials of ipilimumab, a fully human monoclonal antibody against cytotoxic T-lymphocyte antigen-4 (CTLA-4) and, later, the phase III registration study of the same agent. Subsequently, I have continued as a key investigator in the clinical development of the second family of checkpoint inhibitors, anti-PD-1 and anti-PD-L1. A primary focus of my work now involves combinatorial approaches to treatment, combining immune checkpoint blockade with other therapies, including targeted therapies, cytokine therapies and angiogenesis inhibitors. Further, a Phase III trial I led with Jedd Wolchok of Ludwig MSK recently led to the approval of a checkpoint combination, which pairs anti-CTLA-4 and anti-PD-1 therapy for the treatment of melanoma. I am director of the Melanoma Center and the Center for Immuno-Oncology at Dana-Farber/Brigham and Women's Cancer Center and an Assistant Professor of medicine at Harvard Medical School. I received my MD from Cornell University Medical College in 1992, and completed my training in internal medicine at the Hospital of the University of Pennsylvania and my medical oncology training at Dana-Farber Cancer Institute, where I joined the faculty in 1995.
Research Interest
Therapeutics, Immunology, cancer immunotherapy, human monoclonal antibody
Publications
-
Pike LRG, Bang A, Ott P, Balboni T, Taylor A, Catalano P, Rawal B, Spektor A, Krishnan M, Cagney D, Alexander B, Aizer AA, Buchbinder E, Awad M, Gandhi L, Hodi FS, Schoenfeld JD. Radiation and PD-1 inhibition: Favorable outcomes after brain-directed radiation. Radiother Oncol. 2017 Jul; 124(1):98-103.
-
Nishino M, Ramaiya NH, Hatabu H, Hodi FS. Monitoring immune-checkpoint blockade: response evaluation and biomarker development. Nat Rev Clin Oncol. 2017 Jun 27.
-
Long GV, Weber JS, Larkin J, Atkinson V, Grob JJ, Schadendorf D, Dummer R, Robert C, Márquez-Rodas I, McNeil C, Schmidt H, Briscoe K, Baurain JF, Hodi FS, Wolchok JD. Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression: Analysis of 2 Phase 3 Clinical Trials. JAMA Oncol. 2017 Jun 29.
-
Nishino M, Dahlberg SE, Adeni AE, Lydon C, Hatabu H, Janne PA, Hodi FS, Awad MM. Tumor response dynamics of advanced non-small-cell lung cancer patients treated with PD-1 inhibitors: Imaging markers for treatment outcome. Clin Cancer Res. 2017 Jul 05.
